U.S. Markets closed

AVEO Pharmaceuticals, Inc. (AVEO)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7491-0.04 (-4.57%)
At close: 4:00PM EDT
People also watch
PBMDANTHARQLINFIACRX

AVEO Pharmaceuticals, Inc.

One Broadway
14th Floor
Cambridge, MA 02142
United States
617-588-1960
http://www.aveooncology.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees20

Key Executives

NameTitlePayExercisedAge
Mr. Michael P. BaileyChief Exec. Officer, Pres and Director701.31kN/A52
Mr. Keith S. Ehrlich CPAChief Financial Officer451.5kN/A66
Dr. Michael N. Needle M.D.Chief Medical Officer619.49kN/A57
Dr. Emile Farhan Ph.D.VP of Technical OperationsN/AN/AN/A
Ms. Karuna Rubin J.D.VP of Legal Affairs and Corp. Sec.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Corporate Governance

AVEO Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.